Omeprazole - Overview and opinion

S. Holt, Colin Howden

Research output: Contribution to journalReview article

89 Citations (Scopus)

Abstract

Omeprazole, a substituted benzimidazole, is a specific inhibitor of the enzyme H+/K+-ATPase, which is found on the secretory surface of the parietal cell. This enzyme, the "proton pump", catalyzes the final step in acid secretion. Omeprazole is a powerful inhibitor of gastric acid secretion. At the time of writing, omeprazole has been licensed in the United States for the treatment of severe grades of gastroesophageal reflux disease (GERD) as well as GERD unresponsive to treatment with currently available agents, and for the treatment of Zollinger-Ellison syndrome and other gastric hypersecretory states. Most recently, it has been recommended by the FDA advisory committee for approval as first-line therapy in duodenal ulcer disease.

Original languageEnglish (US)
Pages (from-to)385-393
Number of pages9
JournalDigestive Diseases and Sciences
Volume36
Issue number4
DOIs
StatePublished - Apr 1 1991
Externally publishedYes

Fingerprint

Omeprazole
Gastroesophageal Reflux
Duodenal Diseases
Zollinger-Ellison Syndrome
Proton Pumps
Proton-Translocating ATPases
Gastric Acid
Enzyme Inhibitors
Advisory Committees
Duodenal Ulcer
Stomach
Acids
Enzymes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Omeprazole - Overview and opinion. / Holt, S.; Howden, Colin.

In: Digestive Diseases and Sciences, Vol. 36, No. 4, 01.04.1991, p. 385-393.

Research output: Contribution to journalReview article

Holt, S. ; Howden, Colin. / Omeprazole - Overview and opinion. In: Digestive Diseases and Sciences. 1991 ; Vol. 36, No. 4. pp. 385-393.
@article{500b0aee7818470cb4393ffa0e1ab5d1,
title = "Omeprazole - Overview and opinion",
abstract = "Omeprazole, a substituted benzimidazole, is a specific inhibitor of the enzyme H+/K+-ATPase, which is found on the secretory surface of the parietal cell. This enzyme, the {"}proton pump{"}, catalyzes the final step in acid secretion. Omeprazole is a powerful inhibitor of gastric acid secretion. At the time of writing, omeprazole has been licensed in the United States for the treatment of severe grades of gastroesophageal reflux disease (GERD) as well as GERD unresponsive to treatment with currently available agents, and for the treatment of Zollinger-Ellison syndrome and other gastric hypersecretory states. Most recently, it has been recommended by the FDA advisory committee for approval as first-line therapy in duodenal ulcer disease.",
author = "S. Holt and Colin Howden",
year = "1991",
month = "4",
day = "1",
doi = "10.1007/BF01298864",
language = "English (US)",
volume = "36",
pages = "385--393",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Omeprazole - Overview and opinion

AU - Holt, S.

AU - Howden, Colin

PY - 1991/4/1

Y1 - 1991/4/1

N2 - Omeprazole, a substituted benzimidazole, is a specific inhibitor of the enzyme H+/K+-ATPase, which is found on the secretory surface of the parietal cell. This enzyme, the "proton pump", catalyzes the final step in acid secretion. Omeprazole is a powerful inhibitor of gastric acid secretion. At the time of writing, omeprazole has been licensed in the United States for the treatment of severe grades of gastroesophageal reflux disease (GERD) as well as GERD unresponsive to treatment with currently available agents, and for the treatment of Zollinger-Ellison syndrome and other gastric hypersecretory states. Most recently, it has been recommended by the FDA advisory committee for approval as first-line therapy in duodenal ulcer disease.

AB - Omeprazole, a substituted benzimidazole, is a specific inhibitor of the enzyme H+/K+-ATPase, which is found on the secretory surface of the parietal cell. This enzyme, the "proton pump", catalyzes the final step in acid secretion. Omeprazole is a powerful inhibitor of gastric acid secretion. At the time of writing, omeprazole has been licensed in the United States for the treatment of severe grades of gastroesophageal reflux disease (GERD) as well as GERD unresponsive to treatment with currently available agents, and for the treatment of Zollinger-Ellison syndrome and other gastric hypersecretory states. Most recently, it has been recommended by the FDA advisory committee for approval as first-line therapy in duodenal ulcer disease.

UR - http://www.scopus.com/inward/record.url?scp=0025904194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025904194&partnerID=8YFLogxK

U2 - 10.1007/BF01298864

DO - 10.1007/BF01298864

M3 - Review article

C2 - 2007354

AN - SCOPUS:0025904194

VL - 36

SP - 385

EP - 393

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -